Dosing for Personalized Prophylaxis in Hemophilia A Highly Varies on the Underlying Population Pharmacokinetic Models

Conclusions: One model performed best across the population (bias: −3.8 hours a priori, −1.0 hours a posteriori, and 0.6 hours general model fit) and acceptably predicted 44% (a priori) to 90% (general model fit) of the patients. To allow the community-based evaluation of patient–individual FVIII dosing, this model was implemented in the open-access model-informed precision dosing software “TDMx.”
Source: Therapeutic Drug Monitoring - Category: Drugs & Pharmacology Tags: Original Article Source Type: research